Machine Learning-Based Prediction of Drug-Drug Interactions for Histamine Antagonist Using Hybrid Chemical Features

Application of Artificial Intelligence in Drug-Drug Interactions Prediction: A Review

Drug-drug interactions (DDI) are a critical aspect of drug research that can have adverse effects on patients and can lead to serious consequences. Predicting these events accurately can significantly improve clinicians' ability to make better decisions and establish optimal treatment regimens. However, manually detecting these interactions is time-consuming and labor-intensive. Utilizing the advancements in Artificial Intelligence (AI) is essential for achieving accurate forecasts of DDIs. In this review, DDI prediction tasks are classified into three types according to the type of DDI prediction: undirected DDI prediction, DDI events prediction, and Asymmetric DDI prediction. The paper then reviews the progress of AI for each of these three prediction tasks in DDI and provides a summary of the data sets used as well as the representative methods used in these three prediction directions. In this review, we aim to provide a comprehensive overview of drug interaction prediction. The first section introduces commonly used databases and presents an overview of current research advancements and techniques across three domains of DDI. Additionally, we introduce classical machine learning techniques for predicting undirected drug interactions and provide a timeline for the progression of the predicted drug interaction events. At last, we debate the difficulties and prospects of AI approaches at predicting DDI, emphasizing their potential for improving clinical decision-making and patient outcomes.

Comprehensive Review of Drug-Drug Interaction Prediction Based on Machine Learning: Current Status, Challenges, and Opportunities

Detecting drug-drug interactions (DDIs) is an essential step in drug development and drug administration. Given the shortcomings of current experimental methods, the machine learning (ML) approach has become a reliable alternative, attracting extensive attention from the academic and industrial fields. With the rapid development of computational science and the growing popularity of cross-disciplinary research, a large number of DDI prediction studies based on ML methods have been published in recent years. To give an insight into the current situation and future direction of DDI prediction research, we systemically review these studies from three aspects: (1) the classic DDI databases, mainly including databases of drugs, side effects, and DDI information; (2) commonly used drug attributes, which focus on chemical, biological, and phenotypic attributes for representing drugs; (3) popular ML approaches, such as shallow learning-based, deep learning-based, recommender system-based, and knowledge graph-based methods for DDI detection. For each section, related studies are described, summarized, and compared, respectively. In the end, we conclude the research status of DDI prediction based on ML methods and point out the existing issues, future challenges, potential opportunities, and subsequent research direction.

Explainability and white box in drug discovery

Recently, artificial intelligence (AI) techniques have been increasingly used to overcome the challenges in drug discovery. Although traditional AI techniques generally have high accuracy rates, there may be difficulties in explaining the decision process and patterns. This can create difficulties in understanding and making sense of the outputs of algorithms used in drug discovery. Therefore, using explainable AI (XAI) techniques, the causes and consequences of the decision process are better understood. This can help further improve the drug discovery process and make the right decisions. To address this issue, Explainable Artificial Intelligence (XAI) emerged as a process and method that securely captures the results and outputs of machine learning (ML) and deep learning (DL) algorithms. Using techniques such as SHAP (SHApley Additive ExPlanations) and LIME (Locally Interpretable Model-Independent Explanations) has made the drug targeting phase clearer and more understandable. XAI methods are expected to reduce time and cost in future computational drug discovery studies. This review provides a comprehensive overview of XAI-based drug discovery and development prediction. XAI mechanisms to increase confidence in AI and modeling methods. The limitations and future directions of XAI in drug discovery are also discussed.

Analysis and identification of drug similarity through drug side effects and indications data

BACKGROUND

The measurement of drug similarity has many potential applications for assessing drug therapy similarity, patient similarity, and the success of treatment modalities. To date, a family of computational methods has been employed to predict drug-drug similarity. Here, we announce a computational method for measuring drug-drug similarity based on drug indications and side effects.

METHODS

The model was applied for 2997 drugs in the side effects category and 1437 drugs in the indications category. The corresponding binary vectors were built to determine the Drug-drug similarity for each drug. Various similarity measures were conducted to discover drug-drug similarity.

RESULTS

Among the examined similarity methods, the Jaccard similarity measure was the best in overall performance results. In total, 5,521,272 potential drug pair's similarities were studied in this research. The offered model was able to predict 3,948,378 potential similarities.

CONCLUSION

Based on these results, we propose the current method as a robust, simple, and quick approach to identifying drug similarity.

Cutting-Edge Methods for Better Understanding Cells

Cells are microscopic yet fundamental elements of life [...].

Prediction of drug-drug interaction events using graph neural networks based feature extraction

The prevalence of multi_drug therapies has been increasing in recent years, particularly among the elderly who are suffering from several diseases. However, unexpected Drug_Drug interaction (DDI) can cause adverse reactions or critical toxicity, which puts patients in danger. As the need for multi_drug treatment increases, it's becoming increasingly necessary to discover DDIs. Nevertheless, DDIs detection in an extensive number of drug pairs, both in-vitro and in-vivo, is costly and laborious. Therefore, DDI identification is one of the most concerns in drug-related researches. In this paper, we propose GNN-DDI, a deep learning-based method for predicting DDI-associated events in two stages. In the first stage, we collect the drugs information from different sources and then integrate them through the formation of an attributed heterogeneous network and generate a drug embedding vector based on different drug interaction types and drug attributes. In the second stage, we aggregate the representation vectors then predictions of the DDIs and their events are performed through a deep multi-model framework. Various evaluation results show that the proposed method can outperform state-of-the methods in the prediction of drug-drug interaction-associated events. The experimental results indicate that producing the drug's representations based on different drug interaction types and attributes is efficient and effective and can better show the intrinsic characteristics of a drug.

Artificial Intelligence (Enhanced Super-Resolution Generative Adversarial Network) for Calcium Deblooming in Coronary Computed Tomography Angiography: A Feasibility Study

Background: The presence of heavy calcification in the coronary artery always presents a challenge for coronary computed tomography angiography (CCTA) in assessing the degree of coronary stenosis due to blooming artifacts associated with calcified plaques. Our study purpose was to use an advanced artificial intelligence (enhanced super-resolution generative adversarial network [ESRGAN]) model to suppress the blooming artifact in CCTA and determine its effect on improving the diagnostic performance of CCTA in calcified plaques. Methods: A total of 184 calcified plaques from 50 patients who underwent both CCTA and invasive coronary angiography (ICA) were analysed with measurements of coronary lumen on the original CCTA, and three sets of ESRGAN-processed images including ESRGAN-high-resolution (ESRGAN-HR), ESRGAN-average and ESRGAN-median with ICA as the reference method for determining sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV). Results: ESRGAN-processed images improved the specificity and PPV at all three coronary arteries (LAD-left anterior descending, LCx-left circumflex and RCA-right coronary artery) compared to original CCTA with ESRGAN-median resulting in the highest values being 41.0% (95% confidence interval [CI]: 30%, 52.7%) and 26.9% (95% CI: 22.9%, 31.4%) at LAD; 41.7% (95% CI: 22.1%, 63.4%) and 36.4% (95% CI: 28.9%, 44.5%) at LCx; 55% (95% CI: 38.5%, 70.7%) and 47.1% (95% CI: 38.7%, 55.6%) at RCA; while corresponding values for original CCTA were 21.8% (95% CI: 13.2%, 32.6%) and 22.8% (95% CI: 20.8%, 24.9%); 12.5% (95% CI: 2.6%, 32.4%) and 27.6% (95% CI: 24.7%, 30.7%); 17.5% (95% CI: 7.3%, 32.8%) and 32.7% (95% CI: 29.6%, 35.9%) at LAD, LCx and RCA, respectively. There was no significant effect on sensitivity and NPV between the original CCTA and ESRGAN-processed images at all three coronary arteries. The area under the receiver operating characteristic curve was the highest with ESRGAN-median images at the RCA level with values being 0.76 (95% CI: 0.64, 0.89), 0.81 (95% CI: 0.69, 0.93), 0.82 (95% CI: 0.71, 0.94) and 0.86 (95% CI: 0.76, 0.96) corresponding to original CCTA and ESRGAN-HR, average and median images, respectively. Conclusions: This feasibility study shows the potential value of ESRGAN-processed images in improving the diagnostic value of CCTA for patients with calcified plaques.

On the road to explainable AI in drug-drug interactions prediction: a systematic review

•

A systematic review on applications of explainable AI in drug-drug interaction prediction.

•

Review is conducted on a comprehensive set of 94 papers from five prestigious databases.

•

Discussions on the promises and challenges of explainable AI algorithms for drug-drug interaction prediction.

Over the past decade, polypharmacy instances have been common in multi-diseases treatment. However, unwanted drug-drug interactions (DDIs) that might cause unexpected adverse drug events (ADEs) in multiple regimens therapy remain a significant issue. Since artificial intelligence (AI) is ubiquitous today, many AI prediction models have been developed to predict DDIs to support clinicians in pharmacotherapy-related decisions. However, even though DDI prediction models have great potential for assisting physicians in polypharmacy decisions, there are still concerns regarding the reliability of AI models due to their black-box nature. Building AI models with explainable mechanisms can augment their transparency to address the above issue. Explainable AI (XAI) promotes safety and clarity by showing how decisions are made in AI models, especially in critical tasks like DDI predictions. In this review, a comprehensive overview of AI-based DDI prediction, including the publicly available source for AI-DDIs studies, the methods used in data manipulation and feature preprocessing, the XAI mechanisms to promote trust of AI, especially for critical tasks as DDIs prediction, the modeling methods, is provided. Limitations and the future directions of XAI in DDIs are also discussed.

Machine Learning in Drug Metabolism Study

Metabolic reactions in the body transform the administered drug into metabolites. These metabolites exhibit diverse biological activities. Drug metabolism is the major underlying cause of drug overdose-related toxicity, adversative drug effects and the drug's reduced efficacy. Though metabolic reactions deactivate a drug, drug metabolites are often considered pivotal agents for off-target effects or toxicity. On the other side, in combination drug therapy, one drug may influence another drug's metabolism and clearance and is thus considered one of the primary causes of drug-drug interactions. Today with the advancement of machine learning, the metabolic fate of a drug candidate can be comprehensively studied throughout the drug development procedure. Naïve Bayes, Logistic Regression, k-Nearest Neighbours, Decision Trees, different Boosting and Ensemble methods, Support Vector Machines and Artificial Neural Network boosted Deep Learning are some machine learning algorithms which are being extensively used in such studies. Such tools are covering several attributes of drug metabolism, with an emphasis on the prediction of drug-drug interactions, drug-target-interactions, clinical drug responses, metabolite predictions, sites of metabolism, etc. These reports are crucial for evaluating metabolic stability and predicting prospective drug-drug interactions, and can help pharmaceutical companies accelerate the drug development process in a less resourcedemanding manner than what in vitro studies offer. It could also help medical practitioners to use combinatorial drug therapy in a more resourceful manner. Also, with the help of the enormous growth of deep learning, traditional fields of computational drug development like molecular interaction fields, molecular docking, quantitative structure-toactivity relationship (QSAR) studies and quantum mechanical simulations are producing results which were unimaginable couple of years back. This review provides a glimpse of a few contextually relevant machine learning algorithms and then focuses on their outcomes in different studies.